COVID-19与流感疫苗联合接种的免疫原性与安全性
本研究为基于偏好的非随机对照研究,在医护人员中比较mRNA新冠疫苗第三剂与季节性四价流感疫苗联合接种的抗体免疫原性和疫苗相关副作用。结果显示联合接种安全且不增加副作用,但可能限制抗SARS-CoV-2抗体形成。
要点
- 联合接种季节性四价流感疫苗与COVID-19加强针安全,不增加疫苗相关副作用。
- 联合接种可能限制抗SARS-CoV-2抗体形成。
- 研究人群为医护人员,结果外推至一般公众需谨慎。
核心结论
- COVID-19与流感疫苗联合接种安全且不增加副作用,但可能限制抗SARS-CoV-2抗体形成。
研究设计与样本
- 基于偏好的非随机对照研究,在医护人员中比较mRNA新冠疫苗第三剂与季节性四价流感疫苗联合接种。
主要发现
- 联合接种不增加疫苗相关副作用。
- 联合接种可能限制抗SARS-CoV-2抗体形成。
临床怎么用
- 医护人员可考虑联合接种COVID-19加强针与季节性流感疫苗,但需关注抗体应答可能减弱。
局限性
- 为非随机对照研究,存在偏好导致的混杂可能。
- 现有数据外推至一般公众的适用性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coadministration of seasonal quadrivalent influenza and COVID-19 booster vaccination is safe and does not increase vaccine-related side-effects, but may limit anti-SARS-CoV-2 antibody formation https://bit.ly/3uKFUie Seasonal influenza vaccination is established as important infection prevention measure, especially among highly exposed healthcare workers (HCWs) [1]. Coadministration with the third dose of COVID-19 vaccine could be an efficient strategy protecting HCWs from two major viral respiratory infections [2–4]. To date, the humoral immunogenicity and side-effects of a coadministered third COVID-19 and a seasonal quadrivalent influenza vaccine are still unclear, and the available data is limited in transferability to the general public [5–7]. This preference-based non-randomised controlled study examines the antibody-mediated immunogenicity and vaccine-related side-effects of mRNA-based COVID-19 and seasonal influenza vaccine coadministration in HCWs.
引用
- Wagenhäuser I, Reusch J, Gabel A, et al. Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination. Eur Respir J. 2023. PMID: 36549716. doi:10.1183/13993003.01390-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。